The novel treatment targets tear evaporation.
The prescription eye drop Miebo™, containing perfluorohexyloctane, offers a unique approach to managing dry eye disease by specifically targeting tear evaporation. Supported by findings from phase 3 trials, Miebo now provides a distinct option for eye care professionals to better address this widespread condition.
HCN Medical Memo
As physicians, it’s vital to keep abreast of emerging treatments like Miebo™ that offer targeted solutions for prevalent issues like dry eye disease. Miebo not only fills a significant gap by focusing on tear evaporation but also offers convenience with its easy storage and dosing regimen. Given the increasing number of patients struggling with this condition, often exacerbated by screen usage, Miebo offers a promising avenue for treatment.
- Miebo is formulated with perfluorohexyloctane, a semifluorinated alkane that aims at reducing tear evaporation.
- Clinical efficacy was established in phase 3 GOBI and MOJAVE trials, which focused on patients with dry eye disease and signs of meibomian gland dysfunction.
- The recommended dosage is 1 drop applied 4 times daily to affected eyes. The solution is available in a 5mL multiple-dose bottle.
- Contact lens wearers must remove lenses before application and wait at least 30 minutes before reinserting.
- Andrew Stewart, president of Global Pharmaceuticals and International Consumer at Bausch + Lomb, notes that Miebo addresses the leading cause of dry eye disease, attributing the increasing prevalence to “today’s multi-screen lifestyles.”
“More and more Americans are suffering from dry eye disease, due in large part to today’s multi-screen lifestyles.”
– Andrew Stewart, President, Global Pharmaceuticals and International Consumer, Bausch + Lomb
- Miebo can be stored at room temperature and is usable up to the expiration date printed on the bottle.
- The safety and efficacy have not been verified for patients under the age of 18.
More on Drug Approvals in Optometry